Elacestrant: Treatment Considerations, Including Dosing and Compliance

Experts explore treatment considerations when treating patients with metastatic breast cancer with elacestrant, including dosing, patient selection, adherence, and treatment duration. Participants also discuss dose modifications, adherence concerns, and how they determine treatment failure.

Related Keywords

William Gradishar ,Mabel Mardones ,Rena Callahan ,Gregory Vidal ,Peer Exchange ,Oral Serd ,Mbc ,Metastatic Breast Cancer ,Iserd ,Therapeutic Advances ,Panel Discussion ,Her Positive ,Her2 Negative ,Selective Estrogen Receptor Degrader ,Endocrine Therapy ,Targeted Therapy ,Treatment Developments ,Medical Oncology ,Oncologist ,Breast Oncology ,Elacestrant ,Breast Cancer ,Clinical Guidelines ,Fda Label ,Nccn Guidelines ,Esr1 Mutations ,Treatment Resistance ,Moral Therapy ,Disease Progression ,Patient Profiles ,Precision Medicine ,Metastatic Cancer ,Treatment Sequencing ,Liquid Biopsy Tissue Testing ,Precision Oncology ,Therapeutic Strategies ,Treatment Failure Criteria ,Patient Selection ,Dosage Modifications ,Toxicity Comparison ,Breast Cancer Treatment ,